abstract |
The present invention provides a novel cancer treatment method that shows significantly excellent anti-tumor effects and has fewer side effects.nThe present invention provides an antitumor agent, which is characterized in that the epitope 4 linking peptide and the immune checkpoint molecular modulator are administered in combination. Furthermore, by providing a cell that co-expresses the human tumor antigen epitope peptide derived from SART2 and human HLA-A24, the antitumor effect on humans can be evaluated. |